PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08 mars 2024 16h15 HE
|
PharmAla Biotech
PharmAla provides corporate update following AGM
PharmAla named an Intellectual Property Ontario Client
22 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
20 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
09 févr. 2024 08h10 HE
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
31 janv. 2024 10h58 HE
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines
PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada
25 janv. 2024 12h09 HE
|
PharmAla Biotech
PharmAla granted a Health Canada Controlled Drugs and Substances Dealer's License
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
24 janv. 2024 09h35 HE
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
08 janv. 2024 08h55 HE
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
PharmAla Files Audited Financials for Year Ending August 31, 2023
29 déc. 2023 16h00 HE
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
15 nov. 2023 08h55 HE
|
PharmAla Biotech
PharmAla Biotech contracted with Filament Health to manufacture a second batch of MDMA capsules; manufacturing is complete and shipped to clients.